Antengene Presents ATG-207 Preclinical Data at ACR 2026
Shanghai, China, and Hong Kong, November 11, 2026 Antengene Corporation Limited has presented new preclinical findings for ATG-207, an...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Shanghai, China, and Hong Kong, November 11, 2026 Antengene Corporation Limited has presented new preclinical findings for ATG-207, an...
Misgav, Israel, November 9, 2026 Biond Biologics Ltd., a clinical-stage biotechnology company developing innovative immunotherapies, has announced that the...
DEER PARK, Ill. — September 28, 2026 Eton Pharmaceuticals, Inc. announced the U.S. commercial launch of IMPAVIDO® (miltefosine) capsules,...
BOSTON, Mass. — September 28, 2026 Tiziana Life Sciences, Ltd. announced that the first three participants have been dosed...
MIRAMAR, Fla., Sept. 2, 2026 HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune...
Tokyo, Japan – August 27, 2026 Daiichi Sankyo has entered a new phase of oncology development with the first...
MIRAMAR, Fla., August 14, 2026 HCW Biologics Inc. (NASDAQ: HCWB) reported second-quarter 2026 business and clinical development updates, highlighting...
SILVER SPRING, Maryland, June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory...
SILVER SPRING, Maryland, June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, developed by Orca...
INCHEON, South Korea, July 1, 2026 Samsung Bioepis has officially announced the U.S. relaunch of BYOOVIZ® (ranibizumab-nuna), the first...
